Abstract
Purpose: :
To determine the safety of intravitreal administration of 0.5 mg/0.1mL of moxifloxacin (MXF) in an animal model
Methods: :
Prospective, experimental and interventional study using New Zealand adult rabbits and complying with the ARVO statement for the use of animals in ophthalmic and visual research. The right eye (OD) of each rabbit was injected with MXF at a dose of 0.5mg/0.1mL, obtained from a commercially available ophthalmic presentation (Vigamoxi, Alcon, Fort Worth, Texas). Electroretinograms (ERG) were performed at baseline, 7 days, 14 days and 1 month posterior to injection. The left eye (OS) was used as control. The A and B wave and implicit time (IT) in the photopic, scotopic and mesopic phase were analyzed. The experimental eye was enucleated after the last ERG, obtaining sections that were examined under light microscopy.
Results: :
Three rabbits were used. Photopic phase: mean preinjection A wave of 16.53µV, and at 1 month of 13.33µV, mean preinjection B wave of 31.73µV and at 1 month of 29.33 µV, mean preinjection IT of 123.20ms and at 1 month 124.26ms, with minimal variability between all measurements in each variable and with no statistically significant difference between OD and OS (p: 0.661, 0.389 and 0.180, respectively). Scotopic phase: mean preinjection A wave of 30.13µV and at 1 month of 21.33µV, mean preinjection B wave of 55.20µV and at 1 month of 55.20µV, mean preinjection IT of 121.86ms and at 1 month 122.93ms, with minimal variability between all measurements in each variable and with no statistically significant difference between OD and OS (p: 0.655, 0.266 and 0.885, respectively). Mesopic phase: mean preinjection A wave of 12.80µV, and at 1 month of 13.60µV, mean preinjection B wave of 33.86µV and at 1 month of 36.80µV, mean preinjection IT of 122.00ms and at 1 month 139.20ms, with minimal variability between all measurements in each variable and with no statistically significant difference between OD and OS (p: 0.621, 1.00 and 0.470, respectively). The histopathological analysis showed no signs of inflammation or damage to the normal retinal architecture.
Conclusions: :
Intravitreal moxifloxacin at a dose of 0.5mg/0.1ml is safe for its intravitreal administration in an animal model
Keywords: endophthalmitis • drug toxicity/drug effects • electroretinography: clinical